BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 10766157)

  • 1. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T
    Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
    Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
    Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
    Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
    Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
    Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
    Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
    von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
    Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
    Jezersek B; Rudolf Z; Novakovic S
    Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
    Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
    Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
    Lutz W; Nowakowska-Swirta E
    Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
    Sakai H
    Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
    Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
    Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
    Soussi T; Peyrat JP; Lubin R; Bonneterre J
    Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-P53 antibodies in Brazilian brain tumor patients.
    Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
    Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
    Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
    Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
    Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
    Carcinogenesis; 2004 Mar; 25(3):375-80. PubMed ID: 14633656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the anti-p53 antibody response in cancer patients.
    Labrecque S; Naor N; Thomson D; Matlashewski G
    Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical importance of serum anti-p53 antibodies as tumor markers].
    Sakai H; Okamoto E
    Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.